Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2019

Open Access 01-06-2019 | Lung Cancer | short review

Lung cancer screening—the surgeon’s perspective

Authors: Caecilia Ng, Herbert Maier, Florian Augustin, MD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2019

Login to get access

Summary

Results from lung cancer screening trials are promising and show improved survival of lung cancer patients, mainly due to a shift in tumor stages at the time of detection. More lung nodules for histopathologic workup and earlier tumor stages translate into more patients and work load for thoracic surgical units. This article provides a view on lung cancer screening from a thoracic surgeon’s perspective.
Literature
1.
2.
Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergström S, Hanna L, Jakobsen E, Kölbeck K, Sundstrøm S, Engholm G, Gavin A, Gjerstorff ML, Hatcher J, Johannesen TB, Linklater KM, McGahan CE, Steward J, Tracey E, Turner D, Richards MA, Rachet B. ICBP Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68(6):551–64.CrossRef
3.
4.
Tiefenbacher A, Pirker R. Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. Memo. 2018;11(2):112–5.CrossRef
5.
Gamerith G, Kocher F, Rudzki J, Pircher A. ASCO 2018 NSCLC highlights-combination therapy is key. Memo. 2018;11(4):266–71.CrossRef
6.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRef
7.
National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
8.
van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120(4):868–74.CrossRef
9.
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–e66.CrossRef
10.
Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, et al. New Subsolid pulmonary nodules in lung cancer screening: the NELSON trial. J Thorac Oncol. 2018;13(9):1410–4.CrossRef
11.
De Koning H, Van Der Aalst C, Ten Haaf K, et al. Effects of volume CT lung cancer screening: Mortality results of the NELSON randomized-controlled population based trial. World Conference on Lung Cancer; 25.9.2018. 2018. Abstract PL02.05.
12.
Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74.CrossRef
13.
Yang CJ, Wang H, Kumar A, Wang X, Hartwig MG, D’Amico TA, Berry MF. Impact of timing of Lobectomy on survival for clinical stage IA lung squamous cell carcinoma. Chest. 2017;152(6):1239–50.CrossRef
14.
Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol. 2007;2(11):1001–6.CrossRef
15.
Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2553–62.CrossRef
16.
Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836–44.CrossRef
17.
Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, et al. Long-term survival based on the surgical approach to Lobectomy for clinical stage I Nonsmall cell lung cancer: comparison of Robotic, video-assisted thoracic surgery, and Thoracotomy Lobectomy. Ann Surg. 2017;265(2):431–7.CrossRef
18.
Perna V, Carvajal AF, Torrecilla JA, Gigirey O. Uniportal video-assisted thoracoscopic lobectomy versus other video-assisted thoracoscopic lobectomy techniques: a randomized study. Eur J Cardiothorac Surg. 2016;50(3):411–5.CrossRef
19.
AlGhamdi ZM, Lynhiavu L, Moon YK, Moon MH, Ahn S, Kim Y, et al. Comparison of non-intubated versus intubated video-assisted thoracoscopic lobectomy for lung cancer. J Thorac Dis. 2018;10(7):4236–43.CrossRef
20.
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg. 1995;60(3):615–23.CrossRef
21.
Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among Lobectomy, Segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34(26):3175–82.CrossRef
22.
Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study. J Thorac Cardiovasc Surg. 2013;146(2):358–64.CrossRef
23.
Harada H, Okada M, Sakamoto T, Matsuoka H, Tsubota N. Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg. 2005;80(6):2041–5.CrossRef
24.
Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145(1):75–81. discussion 81–2.CrossRef
Metadata
Title
Lung cancer screening—the surgeon’s perspective
Authors
Caecilia Ng
Herbert Maier
Florian Augustin, MD
Publication date
01-06-2019
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0502-9

Other articles of this Issue 2/2019

memo - Magazine of European Medical Oncology 2/2019 Go to the issue

short review

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance

short review

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Correction

Correction to: Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma

case report

Solitary scalp metastatic lesion as a sign of breast cancer recurrence—a case report

editorial

Overcoming resistance and bypassing checkpoints—possible new therapeutic frontiers in oncology

special report

Direct oral anticoagulants: a treatment option in oncological patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits